The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking. New therapeutic approaches using immunotherapy via immune checkpoint blockade， which have demonstrated clinical efficacy in other tumor types， have been less promising in ovarian cancer. To increase their clinical efficacy， checkpoint inhibitors are now being tested in clinical trials in combination with chemotherapy. Here， we evaluated the impact of cisplatin on tumor immunogenicity and its in vivo roles when used alone or in combination with anti-PD-L1， in two novel murine ovarian cancer cell models. The 2F8 and its platinum-resistant derivative 2F8cis model， display distinct inflammatory pro... More
The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking. New therapeutic approaches using immunotherapy via immune checkpoint blockade， which have demonstrated clinical efficacy in other tumor types， have been less promising in ovarian cancer. To increase their clinical efficacy， checkpoint inhibitors are now being tested in clinical trials in combination with chemotherapy. Here， we evaluated the impact of cisplatin on tumor immunogenicity and its in vivo roles when used alone or in combination with anti-PD-L1， in two novel murine ovarian cancer cell models. The 2F8 and its platinum-resistant derivative 2F8cis model， display distinct inflammatory profiles and chemotherapy sensitivities， and mirror the primary and recurrent human disease， respectively. Acute and chronic exposure to cisplatin enhances tumor immunogenicity by increasing calreticulin， MHC class I， antigen presentation and T-cell infiltration. Cisplatin also upregulates PD-L1 expression in vitro and in vivo， demonstrating a dual， paradoxical immune modulatory effect and supporting the rationale for combination with immune checkpoint blockade. One of the pathways activated by cisplatin treatment is the cGAS/STING pathway. Chronic cisplatin treatment led to upregulation of cGAS and STING proteins in 2F8cis compared to parental 2F8 cells， while acute exposure to cisplatin further increases cGAS and STING levels in both 2F8 and 2F8cis cells. Overexpression of cGAS/STING modifies tumor immunogenicity by upregulating PD-L1， MHC I and calreticulin in tumor cells. Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival. These studies have high translational potential in ovarian cancer.
